SG Americas Securities LLC Reduces Stock Holdings in Astrana Health, Inc. (NASDAQ:ASTH)

SG Americas Securities LLC lowered its position in Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 66.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,997 shares of the company's stock after selling 7,745 shares during the quarter. SG Americas Securities LLC's holdings in Astrana Health were worth $126,000 at the end of the most recent quarter.

A number of other hedge funds have also made changes to their positions in ASTH. State Street Corp purchased a new position in shares of Astrana Health in the third quarter valued at $91,966,000. Geode Capital Management LLC purchased a new position in shares of Astrana Health in the third quarter valued at $58,995,000. FMR LLC purchased a new position in shares of Astrana Health in the third quarter valued at $48,413,000. SteelPeak Wealth LLC purchased a new position in shares of Astrana Health in the third quarter valued at $39,398,000. Finally, Loomis Sayles & Co. L P purchased a new position in shares of Astrana Health in the third quarter valued at $30,251,000. Hedge funds and other institutional investors own 52.77% of the company's stock.

Astrana Health Trading Down 0.6 %

NASDAQ:ASTH traded down $0.24 during mid-day trading on Friday, reaching $38.96. The company's stock had a trading volume of 236,589 shares, compared to its average volume of 347,777. The company's fifty day simple moving average is $35.13 and its two-hundred day simple moving average is $45.38. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.91 and a quick ratio of 1.91. Astrana Health, Inc. has a twelve month low of $29.08 and a twelve month high of $63.20. The stock has a market cap of $2.19 billion, a P/E ratio of 29.97, a P/E/G ratio of 1.37 and a beta of 1.20.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ASTH. Macquarie raised Astrana Health to a "hold" rating in a research note on Monday, December 16th. Truist Financial decreased their price objective on Astrana Health from $59.00 to $50.00 and set a "buy" rating on the stock in a research note on Monday, January 13th. Finally, Robert W. Baird increased their price objective on Astrana Health from $67.00 to $86.00 and gave the company an "outperform" rating in a research note on Wednesday, November 13th. Two investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $63.67.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.